Reuters -- Ireland's AGI Therapeutics will widen its focus beyond gastro intestinal disorders and develop alternative uses for its flagship Rezular product after disappointing clinical trials earlier this year.
Reuters -- Ireland's AGI Therapeutics will widen its focus beyond gastro intestinal disorders and develop alternative uses for its flagship Rezular product after disappointing clinical trials earlier this year.
